Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | DHFR | P00374 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | PDE2A | O00408 | 2/20 | 0.30 |
| ▸ | CTSA | P10619 | 1/20 | 0.30 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5109495 | 0.88 | NPC1 (0.33) | — | |
| SCHEMBL5109499 | 0.88 | NPC1 (0.33) | — | |
| SCHEMBL4662901 | 0.86 | CXCR2 (0.33) | KDM4EALDH1A1BRD4CXCR2LMNA | |
| SCHEMBL4664643 | 0.86 | CXCR2 (0.33) | KDM4EALDH1A1BRD4CXCR2LMNA | |
| SCHEMBL5138943 | 0.86 | CXCR2 (0.33) | KDM4EALDH1A1BRD4CXCR2LMNA | |
| SCHEMBL4664676 | 0.79 | CXCR2 (0.34) | KDM4EALDH1A1CXCR2PPARGPPARA | |
| SCHEMBL4664608 | 0.79 | PDK1 (0.32) | KDM4EALDH1A1CXCR2MEN1LMNA | |
| SCHEMBL4962499 | 0.79 | NPC1 (0.33) | CTSA | |
| SCHEMBL5118501 | 0.79 | NPC1 (0.33) | CTSA | |
| SCHEMBL4962514 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113963-A1 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2008-05-15 | — | — | US | disclosed |
| US-7307084-B2 | Cyclic benzimidazoles | ALTANA PHARMA AG (DE) | 2007-12-11 | — | — | US | disclosed |
| US-20060194968-A1 | Cyclic benizimidazoles | ALTANA PHARMA AG (DE) | 2006-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194968-A1 | Cyclic benizimidazoles | VIP, SI, GIPR | KDM4E 1927/4885ALDH1A1 293/4885BRD4 85/4885 |
| US-20080113963-A1 | Cyclic benzimidazoles | VIP, GIPR, SI | KDM4E 3472/4885ALDH1A1 2588/4885BRD4 1068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.